RGD Reference Report - Three generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma: a review. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Three generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma: a review.

Authors: Jalba, MS 
Citation: Jalba MS J Asthma. 2008 Jan-Feb;45(1):9-18.
RGD ID: 5129973
Pubmed: PMID:18259990   (View Abstract at PubMed)
DOI: DOI:10.1080/02770900701495512   (Journal Full-text)

An increase in asthma mortality in 1960s noted by British authors stirred a debate about the use of beta-adrenergic therapy that has persisted in the medical literature. The cause appears to be isoproterenol and fenoterol overuse. A second debate evolved around the possible deleterious, pro-inflammatory effects, of the albuterol distomer. Most clinical studies showed improved bronchodilatation, but limited benefits from using levalbuterol. Recently, genotyping has uncovered a single nucleotide polymorphism at codon 16 that appears to affect the long term response to both regular and as needed use of albuterol, calling for a new genotype based therapeutic approach in asthma.


Additional Information